Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.

Vikash Reebye, Pål Sætrom, Paul J. Mintz, Kai Wen Huang, Piotr Swiderski, Ling Peng, Cheng Liu, Xiaoxuan Liu, Steen Lindkaer-Jensen, Dimitris Zacharoulis, Nikolaos Kostomitsopoulos, Noriyuki Kasahara, Joanna P. Nicholls, Long R. Jiao, Madhava Pai, Duncan R. Spalding, Malkhaz Mizandari, Tinatin Chikovani, Mohamed Emara, Abdelali Haoudi & 3 others Donald A. Tomalia, John J. Rossi, Nagy A. Habib

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) occurs predominantly in patients with liver cirrhosis. Here we show an innovative RNA-based targeted approach to enhance endogenous albumin production while reducing liver tumor burden. We designed short-activating RNAs (saRNA) to enhance expression of C/EBPα (CCAAT/enhancer-binding protein-α), a transcriptional regulator and activator of albumin gene expression. Increased levels of both C/EBPα and albumin mRNA in addition to a 3-fold increase in albumin secretion and 50% decrease in cell proliferation was observed in C/EBPα-saRNA transfected HepG2 cells. Intravenous injection of C/EBPα-saRNA in a cirrhotic rat model with multifocal liver tumors increased circulating serum albumin by over 30%, showing evidence of improved liver function. Tumor burden decreased by 80% (P = 0.003) with a 40% reduction in a marker of preneoplastic transformation. Since C/EBPα has known antiproliferative activities by way of retinoblastoma, p21, and cyclins, we used messenger RNA (mRNA) expression liver cancer-specific microarray in C/EBPα-saRNA-transfected HepG2 cells to confirm down-regulation of genes strongly enriched for negative regulation of apoptosis, angiogenesis, and metastasis. Up-regulated genes were enriched for tumor suppressors and positive regulators of cell differentiation. A quantitative polymerase chain reaction (PCR) and western blot analysis of C/EBPα-saRNA-transfected cells suggested that in addition to the known antiproliferative targets of C/EBPα, we also observed suppression of interleukin (IL)6R, c-Myc, and reduced STAT3 phosphorylation. Conclusion: A novel injectable saRNA-oligonucleotide that enhances C/EBPα expression successfully reduces tumor burden and simultaneously improves liver function in a clinically relevant liver cirrhosis/HCC model.

Original languageEnglish
Pages (from-to)216-227
Number of pages12
JournalHepatology (Baltimore, Md.)
Volume59
Issue number1
Publication statusPublished - 1 Jan 2014

Fingerprint

CCAAT-Enhancer-Binding Proteins
Oligonucleotides
Carcinogenesis
RNA
Liver
Albumins
Tumor Burden
Hep G2 Cells
Liver Cirrhosis
Hepatocellular Carcinoma
Messenger RNA
Cyclins
Retinoblastoma
Interleukins
Liver Neoplasms
Serum Albumin
Intravenous Injections
Genes
Cell Differentiation
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reebye, V., Sætrom, P., Mintz, P. J., Huang, K. W., Swiderski, P., Peng, L., ... Habib, N. A. (2014). Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology (Baltimore, Md.), 59(1), 216-227.

Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. / Reebye, Vikash; Sætrom, Pål; Mintz, Paul J.; Huang, Kai Wen; Swiderski, Piotr; Peng, Ling; Liu, Cheng; Liu, Xiaoxuan; Lindkaer-Jensen, Steen; Zacharoulis, Dimitris; Kostomitsopoulos, Nikolaos; Kasahara, Noriyuki; Nicholls, Joanna P.; Jiao, Long R.; Pai, Madhava; Spalding, Duncan R.; Mizandari, Malkhaz; Chikovani, Tinatin; Emara, Mohamed; Haoudi, Abdelali; Tomalia, Donald A.; Rossi, John J.; Habib, Nagy A.

In: Hepatology (Baltimore, Md.), Vol. 59, No. 1, 01.01.2014, p. 216-227.

Research output: Contribution to journalArticle

Reebye, V, Sætrom, P, Mintz, PJ, Huang, KW, Swiderski, P, Peng, L, Liu, C, Liu, X, Lindkaer-Jensen, S, Zacharoulis, D, Kostomitsopoulos, N, Kasahara, N, Nicholls, JP, Jiao, LR, Pai, M, Spalding, DR, Mizandari, M, Chikovani, T, Emara, M, Haoudi, A, Tomalia, DA, Rossi, JJ & Habib, NA 2014, 'Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.', Hepatology (Baltimore, Md.), vol. 59, no. 1, pp. 216-227.
Reebye V, Sætrom P, Mintz PJ, Huang KW, Swiderski P, Peng L et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology (Baltimore, Md.). 2014 Jan 1;59(1):216-227.
Reebye, Vikash ; Sætrom, Pål ; Mintz, Paul J. ; Huang, Kai Wen ; Swiderski, Piotr ; Peng, Ling ; Liu, Cheng ; Liu, Xiaoxuan ; Lindkaer-Jensen, Steen ; Zacharoulis, Dimitris ; Kostomitsopoulos, Nikolaos ; Kasahara, Noriyuki ; Nicholls, Joanna P. ; Jiao, Long R. ; Pai, Madhava ; Spalding, Duncan R. ; Mizandari, Malkhaz ; Chikovani, Tinatin ; Emara, Mohamed ; Haoudi, Abdelali ; Tomalia, Donald A. ; Rossi, John J. ; Habib, Nagy A. / Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. In: Hepatology (Baltimore, Md.). 2014 ; Vol. 59, No. 1. pp. 216-227.
@article{c9abe6695dc64b8ba009ee247ea42c3e,
title = "Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.",
abstract = "Hepatocellular carcinoma (HCC) occurs predominantly in patients with liver cirrhosis. Here we show an innovative RNA-based targeted approach to enhance endogenous albumin production while reducing liver tumor burden. We designed short-activating RNAs (saRNA) to enhance expression of C/EBPα (CCAAT/enhancer-binding protein-α), a transcriptional regulator and activator of albumin gene expression. Increased levels of both C/EBPα and albumin mRNA in addition to a 3-fold increase in albumin secretion and 50{\%} decrease in cell proliferation was observed in C/EBPα-saRNA transfected HepG2 cells. Intravenous injection of C/EBPα-saRNA in a cirrhotic rat model with multifocal liver tumors increased circulating serum albumin by over 30{\%}, showing evidence of improved liver function. Tumor burden decreased by 80{\%} (P = 0.003) with a 40{\%} reduction in a marker of preneoplastic transformation. Since C/EBPα has known antiproliferative activities by way of retinoblastoma, p21, and cyclins, we used messenger RNA (mRNA) expression liver cancer-specific microarray in C/EBPα-saRNA-transfected HepG2 cells to confirm down-regulation of genes strongly enriched for negative regulation of apoptosis, angiogenesis, and metastasis. Up-regulated genes were enriched for tumor suppressors and positive regulators of cell differentiation. A quantitative polymerase chain reaction (PCR) and western blot analysis of C/EBPα-saRNA-transfected cells suggested that in addition to the known antiproliferative targets of C/EBPα, we also observed suppression of interleukin (IL)6R, c-Myc, and reduced STAT3 phosphorylation. Conclusion: A novel injectable saRNA-oligonucleotide that enhances C/EBPα expression successfully reduces tumor burden and simultaneously improves liver function in a clinically relevant liver cirrhosis/HCC model.",
author = "Vikash Reebye and P{\aa}l S{\ae}trom and Mintz, {Paul J.} and Huang, {Kai Wen} and Piotr Swiderski and Ling Peng and Cheng Liu and Xiaoxuan Liu and Steen Lindkaer-Jensen and Dimitris Zacharoulis and Nikolaos Kostomitsopoulos and Noriyuki Kasahara and Nicholls, {Joanna P.} and Jiao, {Long R.} and Madhava Pai and Spalding, {Duncan R.} and Malkhaz Mizandari and Tinatin Chikovani and Mohamed Emara and Abdelali Haoudi and Tomalia, {Donald A.} and Rossi, {John J.} and Habib, {Nagy A.}",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "59",
pages = "216--227",
journal = "Hepatology (Baltimore, Md.)",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.

AU - Reebye, Vikash

AU - Sætrom, Pål

AU - Mintz, Paul J.

AU - Huang, Kai Wen

AU - Swiderski, Piotr

AU - Peng, Ling

AU - Liu, Cheng

AU - Liu, Xiaoxuan

AU - Lindkaer-Jensen, Steen

AU - Zacharoulis, Dimitris

AU - Kostomitsopoulos, Nikolaos

AU - Kasahara, Noriyuki

AU - Nicholls, Joanna P.

AU - Jiao, Long R.

AU - Pai, Madhava

AU - Spalding, Duncan R.

AU - Mizandari, Malkhaz

AU - Chikovani, Tinatin

AU - Emara, Mohamed

AU - Haoudi, Abdelali

AU - Tomalia, Donald A.

AU - Rossi, John J.

AU - Habib, Nagy A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hepatocellular carcinoma (HCC) occurs predominantly in patients with liver cirrhosis. Here we show an innovative RNA-based targeted approach to enhance endogenous albumin production while reducing liver tumor burden. We designed short-activating RNAs (saRNA) to enhance expression of C/EBPα (CCAAT/enhancer-binding protein-α), a transcriptional regulator and activator of albumin gene expression. Increased levels of both C/EBPα and albumin mRNA in addition to a 3-fold increase in albumin secretion and 50% decrease in cell proliferation was observed in C/EBPα-saRNA transfected HepG2 cells. Intravenous injection of C/EBPα-saRNA in a cirrhotic rat model with multifocal liver tumors increased circulating serum albumin by over 30%, showing evidence of improved liver function. Tumor burden decreased by 80% (P = 0.003) with a 40% reduction in a marker of preneoplastic transformation. Since C/EBPα has known antiproliferative activities by way of retinoblastoma, p21, and cyclins, we used messenger RNA (mRNA) expression liver cancer-specific microarray in C/EBPα-saRNA-transfected HepG2 cells to confirm down-regulation of genes strongly enriched for negative regulation of apoptosis, angiogenesis, and metastasis. Up-regulated genes were enriched for tumor suppressors and positive regulators of cell differentiation. A quantitative polymerase chain reaction (PCR) and western blot analysis of C/EBPα-saRNA-transfected cells suggested that in addition to the known antiproliferative targets of C/EBPα, we also observed suppression of interleukin (IL)6R, c-Myc, and reduced STAT3 phosphorylation. Conclusion: A novel injectable saRNA-oligonucleotide that enhances C/EBPα expression successfully reduces tumor burden and simultaneously improves liver function in a clinically relevant liver cirrhosis/HCC model.

AB - Hepatocellular carcinoma (HCC) occurs predominantly in patients with liver cirrhosis. Here we show an innovative RNA-based targeted approach to enhance endogenous albumin production while reducing liver tumor burden. We designed short-activating RNAs (saRNA) to enhance expression of C/EBPα (CCAAT/enhancer-binding protein-α), a transcriptional regulator and activator of albumin gene expression. Increased levels of both C/EBPα and albumin mRNA in addition to a 3-fold increase in albumin secretion and 50% decrease in cell proliferation was observed in C/EBPα-saRNA transfected HepG2 cells. Intravenous injection of C/EBPα-saRNA in a cirrhotic rat model with multifocal liver tumors increased circulating serum albumin by over 30%, showing evidence of improved liver function. Tumor burden decreased by 80% (P = 0.003) with a 40% reduction in a marker of preneoplastic transformation. Since C/EBPα has known antiproliferative activities by way of retinoblastoma, p21, and cyclins, we used messenger RNA (mRNA) expression liver cancer-specific microarray in C/EBPα-saRNA-transfected HepG2 cells to confirm down-regulation of genes strongly enriched for negative regulation of apoptosis, angiogenesis, and metastasis. Up-regulated genes were enriched for tumor suppressors and positive regulators of cell differentiation. A quantitative polymerase chain reaction (PCR) and western blot analysis of C/EBPα-saRNA-transfected cells suggested that in addition to the known antiproliferative targets of C/EBPα, we also observed suppression of interleukin (IL)6R, c-Myc, and reduced STAT3 phosphorylation. Conclusion: A novel injectable saRNA-oligonucleotide that enhances C/EBPα expression successfully reduces tumor burden and simultaneously improves liver function in a clinically relevant liver cirrhosis/HCC model.

UR - http://www.scopus.com/inward/record.url?scp=84894856234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894856234&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 216

EP - 227

JO - Hepatology (Baltimore, Md.)

JF - Hepatology (Baltimore, Md.)

SN - 0270-9139

IS - 1

ER -